COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
24 hedge funds and large institutions have $1.2M invested in COSCIENS Biopharma Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 5 closing their positions.
0.02% less ownership
Funds ownership: 0.09% → 0.07% (-0.02%)
8% less funds holding
Funds holding: 26 → 24 (-2)
34% less capital invested
Capital invested by funds: $1.83M → $1.2M (-$628K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$34K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$27.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.77K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$93 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$494K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$34.7K |
| 3 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$29K |
| 4 |
VF
Virtu Financial
New York
|
-$27.6K |
| 5 |
Renaissance Technologies
New York
|
-$25.5K |
CSCI Hedge Fund Activity: Q4 2019 in Review
24 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2019, worth a combined $1.2M — down 34% from $1.83M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSCI and 3 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $34K. The largest seller was Armistice Capital, exiting entirely with an estimated $494K sold.
- 24 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2019, down from 26 in Q3 2019.
- Funds reported $1.2M of COSCIENS Biopharma Inc. Common Stock stock for Q4 2019, down 34% quarter-over-quarter.
- 3 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2019 and 5 closed out, a net change of -2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2019 was Morgan Stanley, an estimated $34K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2019 was Armistice Capital, an estimated $494K sold.
Based on aggregated 13F filings for Q4 2019.